论文部分内容阅读
最近,JAMA文献作者Hammer和Grant在肯定了非核苷类似物逆转录酶抑制剂(NNRTI)治疗作用的同时,也指出NNRTI的耐药性将在发达与发展中国家的HIV感染治疗中产生很大影响。 其中Hammer等的研究是在高效抗逆转录病毒疗法(HAART)治疗失败的481例中,比较了两种与一种蛋白酶抑制剂(PI)治疗效果,调查者证实将一种PI加至以安普那韦(Amprenavir, PI)/依法韦伦(NNRTI)为主的方案(PI组)中治疗24周,可使35％患者的HIV-1 RNA浓度降至200拷贝/mL以
Recently, JAMA literature authors Hammer and Grant, while affirming the therapeutic effect of non-nucleoside analog reverse transcriptase inhibitors (NNRTIs), also point out that the drug resistance of NNRTIs will have a significant effect on HIV infection in both developed and developing countries influences. Among them, Hammer et al. Compared the effects of two treatments with a protease inhibitor (PI) in 481 patients who failed HAART, and investigators confirmed the addition of a PI to Isatin Treatment with Amprenavir (PI) / efavirenz (NNRTI) -based regimen (PI) for 24 weeks reduced the concentration of HIV-1 RNA in 35% of patients to 200 copies / mL